Free Newsletter
Conn. sues FDA for OxyContin warnings
If your petition doesn't succeed, go to court. That's what Connecticut Attorney General Richard Blumenthal has done: He's sued the FDA to force the agency to act on his bid for tougher warnings on the painkiller OxyContin, so-called "hillbilly heroin" that is widely abused. At issue, Blumenthal says, is that drug labeling recommends dosing every 12 hours, but 20 percent of all OxyContin scrips were written for dosing every eight hours or less. Drugmaker Purdue Pharma's internal documents show that many docs have been prescribing the drug inappropriately, the AG alleges.
Blumenthal's 2004 petition asked the agency to require Purdue Pharma to strengthen the med's black-box warning and issue a "Dear Healthcare Professional" letter about the shorter-term dosing risks. "The FDA has irresponsibly and illegally ignored the clear need for warnings about OxyContin prescription practices," the AG alleges. "Prescription narcotic abuse of drugs like OxyContin has become the biggest drug threat in the Northeast."
- read the AG's press release
- see the Pharmalot item
- check out the article at Legal Newsline
ALSO: OxyContin abuse in the Seattle area has soared, with the med quickly replacing crystal meth as the recreational drug of choice. Addicts have even been breaking into nursing homes and robbing people's personal medicine chests. Report
Related Articles:
Purdue execs plead guilty to OxyContin fraud. Report
Kentucky sues Purdue over drug abuse. Report
Oxycontin users sue Purdue. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment